Roger K Verbeeck

Summary

Country: Belgium

Publications

  1. ncbi Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
    Roger K Verbeeck
    School of Pharmacy, Catholic University of Louvain, Brussels, Belgium
    Eur J Clin Pharmacol 64:1147-61. 2008
  2. ncbi The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action
    Roger K Verbeeck
    Louvain Drug Research Institute, Pharmacokinetics Drug Metabolism, Catholic University of Louvain, Brussels, Belgium
    J Pharm Pharm Sci 15:376-88. 2012
  3. ncbi Pharmacokinetics and dosage adjustment in patients with renal dysfunction
    Roger K Verbeeck
    Faculty of Pharmacy, Rhodes University, Grahamstown, Eastern Cape, South Africa
    Eur J Clin Pharmacol 65:757-73. 2009
  4. ncbi Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin
    Isabelle K Delattre
    Louvain Centre for Toxicology and applied Pharmacology, Universite Catholique de Louvain, Brussels, Belgium
    Clin Biochem 45:780-6. 2012
  5. ncbi Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus
    Flora T Musuamba
    School of Pharmacy, Faculty of Medicine, Universite Catholique de Louvain, Brussels, Belgium
    Clin Pharmacokinet 48:745-58. 2009
  6. ncbi Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients
    Isabelle K Delattre
    Louvain Centre for Toxicology and applied Pharmacology, Universite Catholique de Louvain, Brussels, Belgium
    Ther Drug Monit 32:749-56. 2010
  7. ncbi Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation
    Flora T Musuamba
    Louvain Drug Research Institute, Universite Catholique de Louvain, Brussels, Belgium Louvain Centre for Toxicology and Applied Pharmacology, Universite Catholique de Louvain, Brussels, Belgium
    Br J Clin Pharmacol 75:1277-88. 2013
  8. ncbi Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis
    Narine Baririan
    Clinical Pharmacology and Gastroenterology Unit, St Luc University Hospital Université Catholique de Louvain, Brussels, Belgium
    Clin Pharmacokinet 46:261-70. 2007
  9. ncbi Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel
    Ralph Nii Okai Tettey-Amlalo
    Faculty of Pharmacy, Rhodes University, P O Box 94, Grahamstown 6140, South Africa
    Eur J Pharm Sci 36:219-25. 2009
  10. ncbi Decreased CYP3A2 expression and activity in senescent male Wistar rats: is there a role for HNF4alpha?
    Valerie Wauthier
    Unité de Pharmacocinétique, Metabolisme, Nutrition et Toxicologie PMNT, département des sciences pharmaceutiques, Universite Catholique de Louvain, Avenue E Mounier 73, 1200, Brussels, Belgium
    Exp Gerontol 41:846-54. 2006

Collaborators

Detail Information

Publications10

  1. ncbi Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
    Roger K Verbeeck
    School of Pharmacy, Catholic University of Louvain, Brussels, Belgium
    Eur J Clin Pharmacol 64:1147-61. 2008
    ..However, the limitations of the Child-Pugh score are acknowledged, and further research is needed to develop more sensitive liver function tests to guide drug dosage adjustment in patients with hepatic dysfunction...
  2. ncbi The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action
    Roger K Verbeeck
    Louvain Drug Research Institute, Pharmacokinetics Drug Metabolism, Catholic University of Louvain, Brussels, Belgium
    J Pharm Pharm Sci 15:376-88. 2012
    ..on topics such as HVDs/HVDPs, NTIDs and BCS-based biowaivers. Global harmonization should be the next logical step to guarantee accessibility to safe and efficacious drug products for patients in all parts of the world...
  3. ncbi Pharmacokinetics and dosage adjustment in patients with renal dysfunction
    Roger K Verbeeck
    Faculty of Pharmacy, Rhodes University, Grahamstown, Eastern Cape, South Africa
    Eur J Clin Pharmacol 65:757-73. 2009
    ..In patients with end-stage renal disease, dialysis techniques such as hemodialysis and continuous ambulatory peritoneal dialysis may remove drugs from the body, necessitating dosage adjustment...
  4. ncbi Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin
    Isabelle K Delattre
    Louvain Centre for Toxicology and applied Pharmacology, Universite Catholique de Louvain, Brussels, Belgium
    Clin Biochem 45:780-6. 2012
    ....
  5. ncbi Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus
    Flora T Musuamba
    School of Pharmacy, Faculty of Medicine, Universite Catholique de Louvain, Brussels, Belgium
    Clin Pharmacokinet 48:745-58. 2009
    ....
  6. ncbi Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients
    Isabelle K Delattre
    Louvain Centre for Toxicology and applied Pharmacology, Universite Catholique de Louvain, Brussels, Belgium
    Ther Drug Monit 32:749-56. 2010
    ..Based on the population estimates, an optimal sampling strategy suitable for Bayesian estimation of the drug PK parameters was developed, meeting the need of clinical practice...
  7. ncbi Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation
    Flora T Musuamba
    Louvain Drug Research Institute, Universite Catholique de Louvain, Brussels, Belgium Louvain Centre for Toxicology and Applied Pharmacology, Universite Catholique de Louvain, Brussels, Belgium
    Br J Clin Pharmacol 75:1277-88. 2013
    ....
  8. ncbi Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis
    Narine Baririan
    Clinical Pharmacology and Gastroenterology Unit, St Luc University Hospital Université Catholique de Louvain, Brussels, Belgium
    Clin Pharmacokinet 46:261-70. 2007
    ....
  9. ncbi Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel
    Ralph Nii Okai Tettey-Amlalo
    Faculty of Pharmacy, Rhodes University, P O Box 94, Grahamstown 6140, South Africa
    Eur J Pharm Sci 36:219-25. 2009
    ..The intra-subject variability was 10% between probes whereas inter-subject variability was 68% (n=18). Bioequivalence was confirmed with a power greater than 90%...
  10. ncbi Decreased CYP3A2 expression and activity in senescent male Wistar rats: is there a role for HNF4alpha?
    Valerie Wauthier
    Unité de Pharmacocinétique, Metabolisme, Nutrition et Toxicologie PMNT, département des sciences pharmaceutiques, Universite Catholique de Louvain, Avenue E Mounier 73, 1200, Brussels, Belgium
    Exp Gerontol 41:846-54. 2006
    ..Our results show that in male senescent rats (1) the decrease of HNF4alpha is not consistent with the continuous secretion of GH, and (2) the suppression of CYP3A2 expression is not dependent to the HNF4alpha binding activity...